Claire Harrison, MD, DM, on Myelofibrosis: Fedratinib as First-Line Therapy After Prior Ruxolitinib

June 24, 2021 By The ASCO Post Staff

Claire Harrison, MD, of Guy’s and St. Thomas’ Hospital, discusses survival results from the JAKARTA and JAKARTA2 trials, which showed that fedratinib, an oral JAK2 inhibitor, significantly improved progression-free survival vs placebo as a first-line treatment for patients with myelofibrosis (Abstract S203).

Related Content